Arcellx, Inc. (NASDAQ:ACLX) revealed new data from its Phase 2 pivotal iMMagine-1 study of anitocabtagene autoleucel ...

In a report released yesterday, Judah Frommer from Morgan Stanley maintained a Buy rating on Arcellx Inc (ACLX – Research Report), with a price ...

Arcellx (NASDAQ:ACLX – Get Free Report)‘s stock had its “buy” rating reiterated by HC Wainwright in a note issued to ...

In a report released today, Richard Newitter from Truist Financial maintained a Buy rating on Arcellx Inc (ACLX – Research Report). The ...

Analysts have recently evaluated Arcellx and provided 12-month price targets. The average target is $107.71, accompanied by a ...

--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable ...

Leerink Partnrs issued their Q1 2025 earnings estimates for shares of Arcellx in a research report issued to clients and ...

GSK, Gilead and Arcellx, Vertex and more present new data at the American Society of Hematology annual meeting just as sickle cell therapies Casgevy and Lyfgenia have a new outcomes-based payment ...

REDWOOD CITY, Calif., November 07, 2024--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with ...

Arcellx, Inc. ( (ACLX)) has released its Q3 earnings. Here is a breakdown of the information Arcellx, Inc. presented to its investors. Unlock your investing potential with TipRanks Premium - Now ...

Anito-cel is partnered with Kite, a Gilead Science Inc’s GILD company. Also Read: Arcellx’s Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson’s Multiple Myeloma ...

Stay informed and make data-driven decisions with the assistance of our Ratings Table. Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of ...